CEO Corner

Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.

There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.

Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.

A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.

The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.

With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.

All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.

Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.